Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | OGG1 | O15527 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4422333 | 0.90 | ALDH1A1 (0.73) | ALDH1A1KMT2AMEN1LMNAKDM4E | |
| SCHEMBL4413701 | 0.85 | ALDH1A1 (0.67) | ALDH1A1KMT2AMEN1LMNAKDM4E | |
| SCHEMBL15426830 | 0.85 | ALDH1A1 (0.68) | ALDH1A1KMT2AMEN1LMNAKDM4E | |
| SCHEMBL1257639 | 0.83 | LMNA (0.63) | KMT2AMEN1LMNASMN1; SMN2GAA | |
| SCHEMBL11547674 | 0.81 | ALDH1A1 (0.63) | ALDH1A1KMT2AMEN1LMNAKDM4E | |
| SCHEMBL11872758 | 0.81 | ALDH1A1 (0.63) | ALDH1A1KMT2AMEN1LMNAKDM4E | |
| SCHEMBL4409512 | 0.81 | ALDH1A1 (0.63) | ALDH1A1KMT2AMEN1LMNAKDM4E | |
| SCHEMBL5434584 | 0.81 | ALDH1A1 (0.63) | ALDH1A1KMT2AMEN1LMNAKDM4E | |
| SCHEMBL1713424 | 0.81 | ALDH1A1 (0.63) | ALDH1A1KMT2AMEN1LMNAKDM4E | |
| SCHEMBL8260422 | 0.81 | LMNA (0.61) | ALDH1A1KMT2AMEN1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130065962-A1 | Compounds For Use In The Treatment Of Diseases | INOXIA LIFESCIENCES GMBH (AT) | 2013-03-14 | — | — | US | claimed |
| CN-102858329-A | Compounds for the treatment of diseases | PLANTA NATURSTOFFE VERTRIEBSGES M B H | 2013-01-02 | — | — | CN | claimed |
| EP-2528595-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES | Inoxia Lifesciences GmbH (AT) | 2012-12-05 | — | — | EP | claimed |
| WO-2011091461-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES | PLANTA NATURSTOFFE VERTRIEBSGES.M.B.H. (AT) | 2011-08-04 | — | — | WO | claimed |
| US-RE50878-E1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2026-05-05 | — | — | US | disclosed |
| US-12528819-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-12291535-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| US-12024525-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| CN-112601749-B | Benzodiazepine derivatives, compositions and methods for treating cognitive impairment | 艾吉因生物股份有限公司 | 2024-03-26 | — | — | CN | disclosed |
| CN-112409363-B | Benzodiazepine derivatives, compositions and methods for the treatment of cognitive impairment | 艾吉因生物股份有限公司 | 2023-11-14 | — | — | CN | disclosed |
| CN-116640143-A | Benzodiazepine derivatives, compositions and methods for treating cognitive impairment | 艾吉因生物股份有限公司 | 2023-08-25 | — | — | CN | disclosed |
| EP-3555100-B1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO INC (US) | 2023-05-10 | — | — | EP | disclosed |
| CN-102858329-A | Compounds for the treatment of diseases | PLANTA NATURSTOFFE VERTRIEBSGES M B H | 2013-01-02 | — | — | CN | disclosed |
| EP-2528595-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES | Inoxia Lifesciences GmbH (AT) | 2012-12-05 | — | — | EP | disclosed |
| US-20110269757-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2011-11-03 | — | — | US | disclosed |
| CN-102159573-A | Pyrazolo pyridine derivatives as nadph oxidase inhibitors | GENKYOTEX SA | 2011-08-17 | — | — | CN | disclosed |
| WO-2011091461-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES | PLANTA NATURSTOFFE VERTRIEBSGES.M.B.H. (AT) | 2011-08-04 | — | — | WO | disclosed |
| EP-2344492-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GenKyoTex SA (CH) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010035221-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2010-04-01 | — | — | WO | disclosed |
| EP-2166010-A1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYO TEX SA (CH) | 2010-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065962-A1 | Compounds For Use In The Treatment Of Diseases | SLC10A1, CYP27A1, OAT | ALDH1A1 353/4885KMT2A 4078/4885MEN1 822/4885 |
| US-20110269757-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | NOX1, NOX4, CYBB | ALDH1A1 230/4885KMT2A 3540/4885MEN1 4672/4885 |
| US-12024525-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | GRM5, GABRA5, GABRE | ALDH1A1 1959/4885KMT2A 2223/4885MEN1 4661/4885 |
| US-12528819-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | GABRA5, GRM5, GABRE | ALDH1A1 2168/4885KMT2A 2203/4885MEN1 4469/4885 |
| US-12291535-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | GABRA5, GRM5, GABRA1 | ALDH1A1 1720/4885KMT2A 835/4885MEN1 3301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.